Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Bert M. Klebl"'
Autor:
Johannes Brägelmann, Marcel A. Dammert, Felix Dietlein, Johannes M. Heuckmann, Axel Choidas, Stefanie Böhm, André Richters, Debjit Basu, Verena Tischler, Carina Lorenz, Peter Habenberger, Zhizhou Fang, Sandra Ortiz-Cuaran, Frauke Leenders, Jan Eickhoff, Uwe Koch, Matthäus Getlik, Martin Termathe, Muhammad Sallouh, Zoltán Greff, Zoltán Varga, Hyatt Balke-Want, Christopher A. French, Martin Peifer, H. Christian Reinhardt, László Örfi, György Kéri, Sascha Ansén, Lukas C. Heukamp, Reinhard Büttner, Daniel Rauh, Bert M. Klebl, Roman K. Thomas, Martin L. Sos
Publikováno v:
Cell Reports, Vol 20, Iss 12, Pp 2833-2845 (2017)
Kinase inhibitors represent the backbone of targeted cancer therapy, yet only a limited number of oncogenic drivers are directly druggable. By interrogating the activity of 1,505 kinase inhibitors, we found that BRD4-NUT-rearranged NUT midline carcin
Externí odkaz:
https://doaj.org/article/65260813004b4d5e8d198b9f59d2baa6
Autor:
Jonas Lategahn, Hannah L. Tumbrink, Carsten Schultz-Fademrecht, Alena Heimsoeth, Lisa Werr, Janina Niggenaber, Marina Keul, Fatma Parmaksiz, Matthias Baumann, Sascha Menninger, Eldar Zent, Ina Landel, Jörn Weisner, Kirujan Jeyakumar, Leonie Heyden, Nicole Russ, Fabienne Müller, Carina Lorenz, Johannes Brägelmann, Inga Spille, Tobias Grabe, Matthias P. Müller, Johannes M. Heuckmann, Bert M. Klebl, Peter Nussbaumer, Martin L. Sos, Daniel Rauh
Publikováno v:
Journal of Medicinal Chemistry. 65:6643-6655
Despite the clinical efficacy of epidermal growth factor receptor (EGFR) inhibitors, a subset of patients with non-small cell lung cancer displays insertion mutations in exon20 in EGFR and Her2 with limited treatment options. Here, we present the dev
Autor:
Laleh S. Arabanian, Jenni Adamsson, Anke Unger, Raffaella Di Lucrezia, Tim Bergbrede, Arghavan Ashouri, Erik Larsson, Peter Nussbaumer, Bert M. Klebl, Lars Palmqvist, Claes M. Gustafsson
Overcoming drug-resistance and the subsequent relapse that often occurs with monotherapy is crucial in the treatment of acute myeloid leukemia. We here demonstrate that therapy-resistant leukemia initiating cells can be targeted using a novel inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb28889780bfe07d28c319720769f2b9
https://doi.org/10.1101/2022.09.23.509145
https://doi.org/10.1101/2022.09.23.509145
Publikováno v:
Cancers 14(18), 4386 (2022). doi:10.3390/cancers14184386
Cancers 14(18), 4386 (2022). doi:10.3390/cancers14184386
Published by MDPI, Basel
Published by MDPI, Basel
Autor:
Bert M Klebl
Publikováno v:
Expert Opinion on Investigational Drugs. 14:343-348
Hepatitis C virus (HCV) and HIV infections are of high economical importance as they have a global impact, high mortality rates and, consequently novel treatments are urgently needed. Worldwide, 170 and 34 – 46 million people are infected with HCV
Publikováno v:
Chemogenomics in Drug Discovery. :167-190
Autor:
Bert M. Klebl
Publikováno v:
Drug discovery today. Technologies. 1(1)
Traditionally, protein kinases have been regarded as non-druggable targets, instead they play a central role in physiological and pathophysiological processes. This changed when STI571, an inhibitor of the Bcr-Abl kinase, known as Gleevec, reached th
Publikováno v:
FEBS Letters. 422:381-384
Sustained contractile activity by chronic low-frequency stimulation in rabbit fast-twitch muscle causes a partial (40–50%) inactivation of the sarcoplasmic reticulum (SR) Ca2+-ATPase and, with prolonged stimulation, a SERCA1a to SERCA2a transition.
Autor:
Dirk Pette, Bert M. Klebl
Publikováno v:
Analytical Biochemistry. 239:145-152
Using 1,N6-etheno NAD, a fluorescent analog of NAD, we extended an existing assay for NAD glycohydrolase to the measurement of mono-ADP-ribosyltransferase (mADP-RT) activity using agmatine as acceptor for ADP-ribose. The reaction products were analyz
Publikováno v:
Archives of biochemistry and biophysics. 347(2)
In order to specify that protein labeling is the result of mono-ADP ribosylation, a careful evaluation of the reaction conditions and products is necessary. To investigate the specificity and target proteins of the arginine-specific mono-ADP-ribosylt